Posted by Michael Wonder on 08 Oct 2025
Vivace Therapeutics' VT3989 granted fast track designation by the US FDA for the treatment of mesothelioma
8 October 2025 - Vivace Therapeutics today announced that the US FDA has granted fast track designation to VT3989, the company's first in class and best in class transcriptional enhanced associate domain autopalmitoylation inhibitor.
The designation pertains to VT3989's use as a treatment for patients with unresectable malignant non-pleural or pleural mesothelioma whose disease has progressed on prior immune checkpoint inhibitor therapy and platinum-based chemotherapy.
